Delamanid
Cross-source consensus on Delamanid from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Delamanid most distinctively signaled decreased haemoglobin across all three analytical contexts. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Delamanid's label explicitly lists dyspnoea, supraventricular extrasystoles, and fever as adverse events. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Delamanid shares cardiac, hepatic, and neurologic signal profiles with bedaquiline. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Delamanid produces metabolite DM-6705, which contributes to QT prolongation through hERG potassium channel inhibition. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Delamanid is preferred over bedaquiline for patients with hepatitis C or antiretroviral therapy because of lower hepatotoxic potential and fewer drug interactions. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database